Related Experiment Video
Updated: Nov 17, 2025

Detecting Anastasis In Vivo by CaspaseTracker Biosensor
Published on: February 1, 2018
Late Effects in Survivors of Neonatal Cancer
Sanyukta K Janardan1, Karen E Effinger1
1Division of Hematology/Oncology/BMT, Department of Pediatrics, Emory University, Atlanta, GA, USA; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, 2015 Uppergate Drive, 4th Floor, Atlanta, GA 30322, USA.
Abstract:
The current 5-year survival rate for cancer in infants is greater than 75% in developed countries. However, survivors of neonatal malignancies have an increased risk of late effects from their tumor or its treatment, which may lead to long-term morbidity and/or early mortality. This article reviews surgical approaches and chemotherapeutic agents commonly used in neonatal malignancies and their associated late effects. It also reviews the increased risk for late effects associated with radiation at a young age and hematopoietic stem cell transplantation at a young age.. It highlights the importance of survivor-specific multidisciplinary care in the long-term management of neonatal cancer survivors.
Related Concept Videos
Cancer Survival Analysis
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Treatment Resistant Cancers
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Teratogenicity
Pharmacokinetics in Pediatric Patients: Drug Excretion

